Clearstead Advisors’s Lucid Diagnostics LUCD Stock Holding History

Clearstead Advisors’s Portfolio LUCD Stock Details LUCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1	Closed	-$2	–	3048
2025 Q3	$2	Buy	+1	New	+$1	﹤0.01%	3081

Other funds holding LUCD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCM

Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Clearstead Advisors's LUCD Position: Q4 2025 in Review

Clearstead Advisors sold out of Lucid Diagnostics (LUCD) in Q4 2025, closing a stake of 1 share — an estimated $2 sold.

Clearstead Advisors first reported a position in LUCD in Q3 2025 and held it in 1 quarter. The position peaked at $2 in Q3 2025. 89 funds tracked by Wall St. Rank hold LUCD as of Q4 2025.

Clearstead Advisors reported no remaining Lucid Diagnostics position as of Q4 2025 after selling out during the quarter.
Clearstead Advisors sold 1 Lucid Diagnostics share in Q4 2025, an estimated $2.
Clearstead Advisors first reported a position in Lucid Diagnostics in Q3 2025 and held it in 1 quarter.
Clearstead Advisors's Lucid Diagnostics position peaked at $2 in Q3 2025.
89 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q4 2025.

Based on Clearstead Advisors's 13F filing for Q4 2025, filed 9 Feb 2026.